All patients (n = 24,676) | Relocation (n = 5888,23.9%) | Non-relocation (n = 18,788, 76.1%) | |
---|---|---|---|
Gender (Male) | 15,172 (61.5%) | 3498 (59.4%) | 11,674 (62.1%) |
Age (years) | 60.3 (15.4) | 55.4 (16.2) | 61.8 (14.8) |
Race | |||
Caucasian | 18,142 (74.1%) | 3876 (66.0%) | 14,266 (76.6%) |
Asian | 2274 (9.3%) | 517 (8.8%) | 1757 (9.4%) |
ATSI | 2669 (10.9%) | 1131 (19.3%) | 1538 (8.3%) |
MPI | 765 (3.1%) | 226 (3.8%) | 539 (2.9%) |
Other | 635 (2.6%) | 121 (2.1%) | 514 (2.8%) |
Comorbidities | |||
Any | 16,228 (65.8%) | 3781 (64.2%) | 12,447 (66.2%) |
Diabetes | 11,570 (47.0%) | 2853 (48.5%) | 8717 (46.5%) |
CLD | 3021 (12.7%) | 641 (11.3%) | 2380 (13.1%) |
CAD | 8077 (34.7%) | 1765 (31.6%) | 6312 (35.7%) |
PVD | 4306 (18.6%) | 993 (17.9%) | 3313 (18.8%) |
CerebVD | 2775 (11.6%) | 610 (10.6%) | 5156 (11.9%) |
Cause of Primary Renal Disease | |||
Glomerulonephritis | 5494 (22.4%) | 1446 (24.6%) | 4048 (21.7%) |
Diabetes | 8803 (35.9%) | 2265 (38.5%) | 6538 (35.0%) |
Hypertension | 3262 (13.3%) | 663 (11.3%) | 2599 (13.9%) |
Cystic disease | 1751 (7.1%) | 392 (6.7%) | 1359 (7.3%) |
Other | 5242 (21.4%) | 1117 (19.0%) | 4125 (22.1%) |
First RRT modality | |||
Facility HD | 17,363 (70.4%) | 5888 (73.8%) | 13,015 (69.3%) |
Home Therapies | 6430 (26.1%) | 1331 (22.6%) | 5099 (27.1%) |
Transplant | 883 (3.6%) | 209 (3.5%) | 674 (3.6%) |
RRT modality at relocation or censoring | |||
Facility HD | 14,331 (58.1%) | 3617 (61.4%) | 10,714 (57.0%) |
Home Therapies | 5750 (23.3%) | 1433 (24.3%) | 4317 (23.0%) |
Transplant | 4595 (18.6%) | 838 (14.2%) | 3757 (20.0%) |
Urbanity | |||
Major | 16,433 (66.6%) | 3652 (62.6%) | 12,781 (68.1%) |
Inner Regional | 4301 (17.5%) | 805 (13.8%) | 3496 (18.6%) |
Outer Regional | 2397 (9.7%) | 599 (10.3%) | 1798 (9.6%) |
Remote | 635 (2.6%) | 214 (3.7%) | 421 (2.2%) |
Very Remote | 843 (3.4%) | 567 (9.7%) | 276 (1.5%) |